Aurion Biotech, INC

S-1

New Public Companies (S-1)

AURN
Aurion Biotech, INC
S-1: Aurion Biotech Files for IPO, Aiming to Revolutionize Corneal Endothelial Disease Treatment
Aurion Biotech, a clinical-stage biotech firm, is seeking an IPO to advance its regenerative therapies for corneal endothelial diseases, including its lead candidate AURN001.
Capital raise